

Scancell

H125 reaffirms funds are sufficient to deliver key data

30 January 2025

- Scancell's interim H125 results (to 31 October 2024) show an operating loss of £10.5m (H124: loss of £8.1m), with R&D the major spend at £8.0m (H124: £5.7m) reflecting increased costs for SCIB1/iSCIB1+ manufacturing and the SCOPE Phase II trial. G&A was flat at £2.5m (H124: £2.4m). Reported net loss expanded to £12.5m (H124: £2.5m) largely owing to non-cash movements relating to the Redmile convertible loan.
- End-October 2024 cash was £9.1m (H124: £14.8m), reflecting net cash use of £5.7m in the period. Post-period the December over-subscribed equity raise brought in £11.3m (gross). This, coupled with £3.9m (\$5.0m) from Genmab's licensing of a second GlyMab (SC2811) and R&D tax credits of £2.7m received in January, mean the cash runway extends to H226. This is beyond the key near-term milestones.
- Key clinical data are expected during 2025 from both the Phase II [SCOPE](#) study and the Phase I/II [ModiFY](#) trial; the progress and background to the ImmunoBody and Moditope oncology vaccine clinical programmes were detailed in our [January 2025 Update](#). For **SCOPE** (in advanced melanoma), data readouts include: (1) full SCIB1 Cohort 1 data for 43 patients as they complete 25 weeks ORR readout, due mid-2025; (2) full iSCIB1+ Cohort 3 data at the 25-week ORR readout, now fully recruited with 43 patients, expected in H225; and (3) early Cohort 4 data, which explores the use of PharmaJet's Tropis intra-dermal delivery system, also due in H225. Collectively these should allow the selection of the optimal vaccine to employ in the potentially pivotal Phase II/III trial programme. For **ModiFY**, early data in the RCC (renal cell carcinoma) cohort exploring Modi-1 with double checkpoint inhibitors (CPIs) are expected in H225.
- The GlyMab platform already has two deals in place with antibody expert Genmab, providing powerful validation of the scientific, clinical, and commercial appeal. This platform, together with AvidiMab, could be a source of future deal(s) and provide attractive out-licensing opportunities.

Price	9.66p
Market Cap	£100.2m
Primary exchange	AIM
Sector	Healthcare
Company Code	SCLP
Corporate client	Yes

Company description:

Scancell is a clinical-stage immuno-oncology specialist that has four broadly applicable technology platforms. Two are therapeutic vaccines, Moditope and ImmunoBody, and two are antibody based, GlyMab and AvidiMab.

Trinity Delta view: Scancell has the financial resources to progress its two highly promising oncology vaccine platforms (Moditope and ImmunoBody) to key clinical inflection points during 2025. Further data from the ongoing SCOPE trial (Cohort 1 data in mid-2025 and Cohort 3 data in H225), assuming the positive response rates seen in early read-outs is maintained, will help define the optimal vaccine form (SCIB1 or iSCIB1+) and the structure of the potentially pivotal Phase II/III trial. Meanwhile, early data due in H225 from the renal cell cancer cohort of the ModiFY study should provide valuable insights into Modi-1's potential clinical utility when coupled with double CPI therapy. Additionally, with Genmab having effectively validated the value inherent in the GlyMab platform, we expect further licensing deals to be struck. Our current risk adjusted NPV valuation for Scancell is £330m, or 32p per share.

Analysts

Lala Gregorek

lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Philippa Gardner

pgardner@trinitydelta.org
+44 (0) 20 3637 5042

Philippa Gardner

pgardner@trinitydelta.org

+44 (0) 20 3637 5042

Lala Gregorek

lgregorek@trinitydelta.org

+44 (0) 20 3637 5043

Franc Gregori

fgregori@trinitydelta.org

+44 (0) 20 3637 5041

Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2025 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: www.trinitydelta.org